Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial

Gabe S. Sonke, Lowell L. Hart, Mario Campone, Frans Erdkamp, Wolfgang Janni, Sunil Verma, Cristian Villanueva, Erik Jakobsen, Emilio Alba, Erik Wist, Anne M. Favret, Thomas Bachelot, Roberto Hegg, Paul Wheatley-Price, Farida Souami, Santosh Sutradhar, Michelle Miller, Caroline Germa, Howard A. Burris

Open source

DOI: 10.1007/s10549-017-4523-y
Published: 2017-10-22
Container: Breast Cancer Research and Treatment
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s10549-017-4523-y,
  title = {Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial},
  author = {Gabe S. Sonke and Lowell L. Hart and Mario Campone and Frans Erdkamp and Wolfgang Janni and Sunil Verma and Cristian Villanueva and Erik Jakobsen and Emilio Alba and Erik Wist and Anne M. Favret and Thomas Bachelot and Roberto Hegg and Paul Wheatley-Price and Farida Souami and Santosh Sutradhar and Michelle Miller and Caroline Germa and Howard A. Burris},
  year = {2017},
  journal = {Breast Cancer Research and Treatment},
  doi = {10.1007/s10549-017-4523-y},
  url = {https://doi.org/10.1007/s10549-017-4523-y}
}

RIS

TY  - JOUR
TI  - Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial
AU  - Gabe S. Sonke
AU  - Lowell L. Hart
AU  - Mario Campone
AU  - Frans Erdkamp
AU  - Wolfgang Janni
AU  - Sunil Verma
AU  - Cristian Villanueva
AU  - Erik Jakobsen
AU  - Emilio Alba
AU  - Erik Wist
AU  - Anne M. Favret
AU  - Thomas Bachelot
AU  - Roberto Hegg
AU  - Paul Wheatley-Price
AU  - Farida Souami
AU  - Santosh Sutradhar
AU  - Michelle Miller
AU  - Caroline Germa
AU  - Howard A. Burris
PY  - 2017
JO  - Breast Cancer Research and Treatment
DO  - 10.1007/s10549-017-4523-y
UR  - https://doi.org/10.1007/s10549-017-4523-y
ER  -

APA

Sonke, G. S., Hart, L. L., Campone, M., Erdkamp, F., Janni, W., Verma, S., Villanueva, C., Jakobsen, E., Alba, E., Wist, E., Favret, A. M., Bachelot, T., Hegg, R., Wheatley-Price, P., Souami, F., Sutradhar, S., Miller, M., Germa, C., & Burris, H. A. (2017). Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-017-4523-y

Source records

crossref · retrieved 2026-09-26T02:39:19.780Z